Compare FTAI Aviation Ltd (FTAI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Twist Bioscience Corp — how do they compare? FTAI Aviation Ltd trades at $206.67 (market cap $21.93B), while Twist Bioscience Corp trades at $93.31 (market cap $5.76B). The key difference: FTAI Aviation Ltd is far larger — about 3.8× Twist Bioscience Corp's market cap, and FTAI Aviation Ltd pays a 0.7% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| FTAI | TWST | |
|---|---|---|
Market Cap | $21.93B | $5.76B |
Sector | Industrials | Health |
52-Week High | $310.04 | $102.88 |
52-Week Low | $109.92 | $24.16 |
Enterprise Value | $24.97B | $5.69B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $205.71, down 0.25% with a bearish technical outlook despite unanimous analyst buy ratings. The company reported strong revenue growth to $2.51 billion in 2025 with 19% net margins, though recent quarters show earnings misses. Positive developments include a strategic Boeing 737-800 freighter collaboration and expansion into data center power solutions, while negative operating cash flow raises execution concerns.
The stock presents growth potential from aerospace servicing and new power segment opportunities, but faces risks from consistent earnings misses and high valuations (P/E 42.6). Institutional sentiment remains strongly positive with 100% buy ratings, though technical indicators suggest near-term pressure with support at $195.
Twist Bioscience (TWST) trades at $92.61, up 2.5% on the day, with a bullish technical signal and strong analyst support. The company shows improving revenue growth ($377M in 2025, up 20% year-over-year) but continues to report significant losses (-$77.7M net income). Recent AI-driven drug discovery collaborations and product expansions provide growth catalysts, though persistent negative cash flow and insider selling present concerns.
Outlook remains cautiously optimistic with 79% analyst buy ratings and a $91.63 consensus target. Investment opportunity centers on AI-enabled synthetic biology growth, while risks include sustained profitability challenges, cash burn, and competitive pressures in genomics. The stock trades at premium valuations (P/S 13.74) despite negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
